Source:http://linkedlifedata.com/resource/pubmed/id/11222362
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2001-3-6
|
| pubmed:abstractText |
The Dana-Farber Cancer Institute (DFCI) acute lymphoblastic leukemia (ALL) Consortium Protocol 91-01 was designed to improve the outcome of children with newly diagnosed ALL while minimizing toxicity. Compared with prior protocols, post-remission therapy was intensified by substituting dexamethasone for prednisone and prolonging the asparaginase intensification from 20 to 30 weeks. Between 1991 and 1995, 377 patients (age, 0-18 years) were enrolled; 137 patients were considered standard risk (SR), and 240 patients were high risk (HR). Following a 5.0-year median follow-up, the estimated 5-year event-free survival (EFS) +/- SE for all patients was 83% +/- 2%, which is superior to prior DFCI ALL Consortium protocols conducted between 1981 and 1991 (P =.03). There was no significant difference in 5-year EFS based upon risk group (87% +/- 3% for SR and 81% +/- 3% for HR, P =.24). Age at diagnosis was a statistically significant prognostic factor (P =.03), with inferior outcomes observed in infants and children 9 years or older. Patients who tolerated 25 or fewer weeks of asparaginase had a significantly worse outcome than those who received at least 26 weeks of asparaginase (P <.01, both univariate and multivariate). Older children (at least 9 years of age) were significantly more likely to have tolerated 25 or fewer weeks of asparaginase (P <.01). Treatment on Protocol 91-01 significantly improved the outcome of children with ALL, perhaps due to the prolonged asparaginase intensification and/or the use of dexamethasone. The inferior outcome of older children may be due, in part, to increased intolerance of intensive therapy.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0006-4971
|
| pubmed:author |
pubmed-author:ArkinSS,
pubmed-author:AsselinB LBL,
pubmed-author:BarrR DRD,
pubmed-author:ClavellL ALA,
pubmed-author:CohenH JHJ,
pubmed-author:DaltonV KVK,
pubmed-author:DeclerckLL,
pubmed-author:GelberR DRD,
pubmed-author:HurwitzC ACA,
pubmed-author:MoghrabiAA,
pubmed-author:SallanS ESE,
pubmed-author:SamsonYY,
pubmed-author:SchorinM AMA,
pubmed-author:SilvermanL BLB
|
| pubmed:issnType |
Print
|
| pubmed:day |
1
|
| pubmed:volume |
97
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1211-8
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:11222362-Adolescent,
pubmed-meshheading:11222362-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11222362-Asparaginase,
pubmed-meshheading:11222362-Child,
pubmed-meshheading:11222362-Child, Preschool,
pubmed-meshheading:11222362-Clinical Protocols,
pubmed-meshheading:11222362-Dexamethasone,
pubmed-meshheading:11222362-Disease-Free Survival,
pubmed-meshheading:11222362-Doxorubicin,
pubmed-meshheading:11222362-Female,
pubmed-meshheading:11222362-Follow-Up Studies,
pubmed-meshheading:11222362-Humans,
pubmed-meshheading:11222362-Infant,
pubmed-meshheading:11222362-Infant, Newborn,
pubmed-meshheading:11222362-Male,
pubmed-meshheading:11222362-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:11222362-Risk Factors,
pubmed-meshheading:11222362-Treatment Outcome
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.
|
| pubmed:affiliation |
Department of Pediatric Oncology, Dana-Farber Cancer Institute, the Division of Hematology/Oncology, Children's Hospital, Harvard Medical School, Boston, MA 02215, USA. lewis_silverman@dfci.harvard.edu
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial
|